Assoc. Prof. Murat Ayhan

Assoc. Prof. Murat Ayhan is a dedicated medical oncologist affiliated with LIV Hospital Vadistanbul in Istanbul, offering advanced cancer care to local and international patients. He completed his medical training at Dicle University, followed by specialization at Istanbul Medeniyet University’s Göztepe Training and Research Hospital and further service at Kartal City Hospital. In 2023, he earned the academic title of Associate Professor in Medical Oncology, underscoring his clinical and academic competence.

He is actively engaged in research and clinical trials, particularly in areas such as breast cancer, lung cancer, colorectal cancers, gynecological & urogenital cancers, and molecular oncology.

Dr. Ayhan has contributed significantly to oncology literature. His publications include studies on neoadjuvant chemotherapy for breast cancer, real‑world data for lung cancer treatments (e.g. tyrosine kinase inhibitors), treatment outcomes in gastric and colorectal cancers, and safety/efficacy analyses of therapies in metastatic cancers.

He is a member of recognized oncology societies including European Society for Medical Oncology (ESMO) and Turkish Society of Medical Oncology (TTOD).

• Medical degree: Faculty of Medicine, Dicle University.
• Further training: Istanbul Medeniyet University (Göztepe Training and Research Hospital)
• Additional affiliation: Kartal City Hospital (as per his profile history)
• Academic title: Associate Professor of Medical Oncology (awarded in 2023)

• Breast cancer
• Lung cancer (non‑small cell lung cancer, others)
• Colorectal cancer (colon and rectal cancers)
• Gynecological and urogenital cancers (including hormone‑receptor positive, HER2‑negative, metastatic cancers)
• Advanced / metastatic cancers requiring molecular oncology / targeted therapy / immunotherapy / systemic therapy.

• Chemotherapy cost in turkey
• Immunotherapy
• Systemic chemotherapy regimens for various cancers (breast, colorectal, lung, gastric, etc.)
• Targeted therapies and biologic agents (as part of molecular oncology protocols)
• Immunotherapies (e.g. checkpoint inhibitors) especially in lung cancer and melanoma settings.
• Personalized cancer care including biomarker‑based therapies and real‑world treatment plans for metastatic disease.
• Participation in international clinical trials for new oncology treatments (phases II/III) for breast cancer, lung cancer, prostate cancer, urothelial cancer, etc.